Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones

Core Insights - Mural Oncology is focused on advancing its clinical-stage immuno-oncology therapies, particularly the nemvaleukin program, with significant data readouts expected in 2025 [2][18]. Upcoming Milestones - Interim overall survival analysis for the phase 3 ARTISTRY-7 trial in platinum-resistant ovarian cancer is anticipated in late Q1/early Q2 2025 [4][18]. - Top-line data from the phase 2 ARTISTRY-6 trial in mucosal melanoma is expected in Q2 2025 [4][18]. - Preliminary data for less-frequent intravenous dosing of nemvaleukin alfa in ARTISTRY-6 for cutaneous melanoma is expected in 1H 2025 for monotherapy and 2H 2025 for combination therapy [4][8][9]. Financial Performance - As of December 31, 2024, Mural's cash, cash equivalents, and marketable securities totaled $144.4 million, extending the cash runway into Q1 2026 [11][16]. - Research and development expenses decreased to$28.7 million in Q4 2024 from $42.2 million in Q4 2023, attributed to reduced employee-related expenses and trial winding down [12][13]. - General and administrative expenses also decreased to$7.2 million in Q4 2024 from $16.3 million in Q4 2023, primarily due to lower employee-related expenses [14]. Clinical Development - The ARTISTRY-7 trial is evaluating nemvaleukin alfa in combination with pembrolizumab against single-agent chemotherapy in platinum-resistant ovarian cancer, with a high statistical bar for success at the interim analysis [4][18]. - The ARTISTRY-6 trial, cohort 2, targets a response rate of 25% in patients with unresectable or metastatic mucosal melanoma, with Orphan Drug Designation granted by the FDA [7][18]. - Mural is also developing MURA-8518 and MURA-7012, targeting IL-18 and IL-12 respectively, with plans for IND submission for MURA-8518 in 1H 2026 [10][19][20].